| Literature DB >> 32298656 |
Irina Leonardi1, Sudarshan Paramsothy2, Itai Doron1, Alexa Semon1, Nadeem O Kaakoush3, Jose C Clemente4, Jeremiah J Faith4, Thomas J Borody5, Hazel M Mitchell3, Jean-Frederic Colombel4, Michael A Kamm6, Iliyan D Iliev7.
Abstract
Fecal microbiota transplantation (FMT) targeting gut microbiota has recently been successfully applied to ulcerative colitis. However, only a subset of patients responds to FMT, and there is a pressing need for biomarkers of responsiveness. Fungi (the mycobiota) represent a highly immunologically reactive component of the gut microbiota. We analyzed samples from a large randomized controlled trial of FMT for ulcerative colitis (UC). High Candida abundance pre-FMT was associated with a clinical response, whereas decreased Candida abundance post-FMT was indicative of ameliorated disease severity. High pre-FMT Candida was associated with increased bacterial diversity post-FMT, and the presence of genera was linked to FMT responsiveness. Although we detected elevated anti-Candida antibodies in placebo recipients, this increase was abrogated in FMT recipients. Our data suggest that FMT might reduce Candida to contain pro-inflammatory immunity during intestinal disease and highlight the utility of mycobiota-focused approaches to identify FMT responders prior to therapy initiation.Entities:
Keywords: Candida; fecal microbiota transplantation; gut fungi; mycobiota; ulcerative colitis
Mesh:
Substances:
Year: 2020 PMID: 32298656 DOI: 10.1016/j.chom.2020.03.006
Source DB: PubMed Journal: Cell Host Microbe ISSN: 1931-3128 Impact factor: 21.023